Cardiovascular Disease and Type 2 Diabetes: Defining the Therapeutic Crossroads

Release Date: Wednesday, March 24, 2021
Expiration Date: Thursday, September 30, 2021

Launch Presentation Download Handout

The risk of cardiovascular disease (CVD) and cardiovascular (CV) events are increased in patients with diabetes, despite management of CV risk factors with established therapies. New guidelines recommend a CVD-centric approach to manage hyperglycemia. This activity explores primary and secondary CV prevention strategies, including lifestyle, lipids, blood pressure, glycemic control, and long-term oral antiplatelet trials in secondary prevention.

Learning Objectives

  • Summarize the relationships between type 2 diabetes (T2D), cardiovascular disease (CVD), and CVD risk factors.
  • Define primary and secondary prevention of CVD.
  • Apply current management strategies for comorbidities in patients with T2D.
  • Explain primary and secondary cardiovascular prevention in patients with type 2 diabetes.

        This webinar is not accredited for continuing education. 


Curtis L. Triplitt, Pharm.D., CDCES, FADCES
Clinical Associate Professor, Medicine/Diabetes
University of Texas Health Science Center at San Antonio
Associate Director, Diabetes Research
Texas Diabetes Institute, University Health System
San Antonio, Texas


In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.

In this activity, only the individual/s below has disclosed a relevant financial relationship.  No other persons associated with this presentation have disclosed any relevant financial relationships.

Curtis L. Triplitt, Pharm.D., CDCES, FADCES

  • AstraZeneca Pharmaceuticals,* Eli Lilly and Company, Novo Nordisk, Xeris Pharmaceuticals*: Speakers bureau
    *Divested himself of relationship within last 12 months
Target Audience

This activity was planned to meet the educational needs of pharmacists and pharmacist decision makers who care for or have an interest in the care of patients with type 2 diabetes.